Fiche société
Verastem, Inc.
Traitements, essais et publications liés.
Traitements8programmes
Essais4liés
Publications11liées
SourceDBlocale
Traitements
8| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| CetuximabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Cancer, Parkinson | Phase 2 | À vérifier | United States, Australia | À vérifier |
| Cetuximab + mFOLFOX6This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer | Cancer | Phase 2 | À vérifier | United States, Australia | À vérifier |
| PanitumumabThere will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort. In the Combination Dose Finding cohort and the Combination Expansion cohort, we will combine cabozantinib and panitumumab in patients with KRAS wild-type metastatic colorectal cancer (CRC). In the Monotherapy MET Amplified cohort, we will screen at least 50 patients for MET gene amplification ("MET amplification"). Patients with MET amplification will receive cabozantinib only (monotherapy). The primary objective of this open-label phase Ib trial are: 1. To determine the maximum tolerated dose and the recommended phase II dose for the combination of cabozantinib and panitumumab in patients with KRAS wild-type metastatic colorectal cancer and 2. To identify the objective response rate (ORR) of cabozantinib monotherapy in patients with prospectively identified MET amplified metastatic colorectal cancer. The secondary objectives are: 1. To describe the non-dose limiting toxicities of cabozantinib and panitumumab. 2. To describe the clinical activity (ORR, PFS, OS) of cabozantinib and panitumumab. 3. To describe the safety and tolerability of cabozantinib monotherapy in patients with MET amplified colorectal cancer. 4. To describe the clinical activity (PFS, OS) of cabozantinib monotherapy in patients with MET amplified colorectal cancer. | Cancer | Phase 2 | À vérifier | United States, Australia | À vérifier |
| VS-7375This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer | Cancer | Phase 2 | À vérifier | United States, Australia, Puerto Rico | À vérifier |
| PanitumumabThere will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort. In the Combination Dose Finding cohort and the Combination Expansion cohort, we will combine cabozantinib and panitumumab in patients with KRAS wild-type metastatic colorectal cancer (CRC). In the Monotherapy MET Amplified cohort, we will screen at least 50 patients for MET gene amplification ("MET amplification"). Patients with MET amplification will receive cabozantinib only (monotherapy). The primary objective of this open-label phase Ib trial are: 1. To determine the maximum tolerated dose and the recommended phase II dose for the combination of cabozantinib and panitumumab in patients with KRAS wild-type metastatic colorectal cancer and 2. To identify the objective response rate (ORR) of cabozantinib monotherapy in patients with prospectively identified MET amplified metastatic colorectal cancer. The secondary objectives are: 1. To describe the non-dose limiting toxicities of cabozantinib and panitumumab. 2. To describe the clinical activity (ORR, PFS, OS) of cabozantinib and panitumumab. 3. To describe the safety and tolerability of cabozantinib monotherapy in patients with MET amplified colorectal cancer. 4. To describe the clinical activity (PFS, OS) of cabozantinib monotherapy in patients with MET amplified colorectal cancer. | Cancer | Phase 1 | À vérifier | United States | À vérifier |
| CetuximabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Cancer | Phase 1 | À vérifier | United States | À vérifier |
| VS-7375This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer | Cancer | Phase 2 | À vérifier | United States, Australia | À vérifier |
| VS-7375This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer | Cancer | Phase 2 | À vérifier | United States, Australia, Puerto Rico | À vérifier |
Essais cliniques
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| VS-7375 | Cancer | Phase 2 | NCT07659782 | TARGET-D 202 — A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer | RECRUITING |
| VS-7375 | Cancer | Phase 2 | NCT07659795 | TARGET-D 203 — A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | RECRUITING |
| Cetuximab | Cancer | Phase 1 | NCT05985954 | Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy | RECRUITING |
| Panitumumab | Cancer | Phase 1 | NCT02008383 | Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer | COMPLETED |
Publications
11| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Panitumumab | Treatment of Human Glioblastoma Multiforme in NRG Mice by Convection-Enhanced Delivery of EGFR-Targeted or Nontargeted Auger Electron-Emitting Hg-Labeled Gold Nanoparticles. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine | ||
| Cetuximab | Internalization-Dependent EGFR-Targeted Photoactivation by Cetuximab-I21 Conjugates. | Journal of immunotherapy (Hagerstown, Md. : 1997) | ||
| Cetuximab | Incidence, treatment variation, and survival of synchronous head and neck and esophageal carcinomas: a descriptive nationwide cohort study in the Netherlands. | ESMO gastrointestinal oncology | ||
| Cetuximab | Novel bispecific T-cell engagers overcoming acquired EGFR resistance. | mAbs | ||
| Panitumumab | HLX07, a novel anti-EGFR antibody, for locally advanced and metastatic cutaneous squamous cell carcinoma: an open-label, multicenter, phase II trial. | Therapeutic advances in medical oncology | ||
| Cetuximab | Therapeutic resistance in HPV-positive oropharyngeal squamous cell carcinoma: molecular mechanisms, clinical challenges, and precision strategies. | Frontiers in genetics | ||
| Cetuximab | Outcomes and Prognostic Factors of Cetuximab-Based Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. | Journal of clinical medicine | ||
| Cetuximab | Conversion strategies in RAS wild-type colorectal liver metastases: a systematic review and meta-analysis of first-line trials comparing regimens with anti-epidermal growth factor receptor inhibitors versus bevacizumab. | Critical reviews in oncology/hematology | ||
| Cetuximab | A Transgenic mouse tolerant to syngeneic cancer cells expressing truncated human epidermal growth factor receptor. | PloS one | ||
| Panitumumab | Durable Response to Sotorasib Plus Panitumumab in NRAS G12C-Mutated, Microsatellite Instability-High (MSI-H) Rectal Cancer Refractory to Immunotherapy. | Cureus | ||
| Panitumumab | Recent advances in fluorescent probes for guided surgery of head and neck carcinomas. | RSC advances |